ALL
Haematology · 2007–2026
18decisions
6medicines
7carried consumer input
24individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| inotuzumab ozogamicin Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (B-ALL), including Philadelphia chromosome-positive disease. | Mar 2026 | Noted | unclear |
| blinatumomab B-cell precursor acute lymphoblastic leukaemia (B-ALL) in complete haematological remission following induction chemotherapy, regardless of measurable residual… | Nov 2024 | Recommended with restriction | input received Leukaemia Foundation · Oncology Group |
| blinatumomab Extension of listing to include patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B-cell precursor acute lymphoblastic leukaemia… | May 2019 | Recommended | no section in document |
| inotuzumab ozogamicin Extension of listing to include relapsed or refractory Philadelphia chromosome positive (Ph+) CD22-positive B-cell precursor acute lymphocytic leukaemia… | May 2019 | Deferred | no section in document |
| blinatumomab Treatment of patients with B-cell precursor acute lymphoblastic leukaemia (B-ALL) in haematological complete remission with minimal residual disease (MRD)… | Mar 2019 | Deferred | 5 individuals |
| dasatinib Newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) in combination with chemotherapy or corticosteroids for induction… | Mar 2019 | Recommended | input received Leukaemia Foundation |
| inotuzumab ozogamicin Treatment of relapsed or refractory Philadelphia chromosome negative, CD22-positive B-cell precursor acute lymphoblastic leukaemia (B-ALL) in adults. | Nov 2018 | Recommended with restriction | input received |
| ponatinib Relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) in patients who have failed or are intolerant to dasatinib but… | Nov 2017 | Recommended | input received |
| blinatumomab Treatment of relapsed or refractory Philadelphia chromosome negative B-precursor acute lymphoblastic leukaemia in adults. | Jul 2016 | Recommended with restriction | 6 individuals |
| blinatumomab Treatment of relapsed or refractory Philadelphia chromosome negative B-precursor acute lymphoblastic leukaemia (Ph-B-precursor ALL) in adults. | Nov 2016 | Recommended with restriction | 13 individuals |
| blinatumomab Treatment of relapsed or refractory Philadelphia negative B-precursor acute lymphoblastic leukaemia (ALL) in adult patients. | Nov 2015 | Not recommended | none received |
| mercaptopurine Treatment of acute lymphoblastic leukaemia in paediatric patients when the tablet form is unsuitable. | Nov 2014 | Recommended | none received |
| dasatinib treatment of adults with acute lymphoblastic leukaemia (ALL), expressing the Philadelphia chromosome or the transcript, bcr-abl kinase, who are resistant to,… | Jul 2007 | Recommended with restriction | no section in document |
| imatinib mesylate treatment of acute lymphoblastic leukaemia (ALL) expressing the Philadelphia chromosome or the transcript, bcr-abl tyrosine kinase, in newly diagnosed patients… | Jul 2007 | Recommended with restriction | no section in document |
| dasatinib Acute lymphoblastic leukaemia (ALL) expressing the Philadelphia chromosome or BCR-ABL transcript in adults who are resistant to or intolerant of prior therapy. | Jul 2007 | Recommended with restriction | no section in document |
| imatinib mesylate Treatment of adult patients with newly diagnosed acute lymphoblastic leukaemia (ALL) expressing the Philadelphia chromosome or bcr-abl tyrosine kinase, in… | Jul 2007 | Recommended with restriction | no section in document |
| dasatinib Treatment of acute lymphoblastic leukaemia (ALL) in adult patients expressing the Philadelphia chromosome or transcript, bcr-abl tyrosine kinase, who are… | Mar 2007 | Recommended | no section in document |
| dasatinib Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL) who are resistant or intolerant to prior therapy. | Mar 2007 | Recommended | no section in document |
Who spoke
Leukaemia Foundation · Oncology Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 12 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.